Regeneron Pharmaceuticals (REGN) News Today $701.85 -6.40 (-0.90%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Regeneron’s Promising Drug Pipeline and Strong Safety Profile Justify Buy RatingDecember 21 at 2:23 AM | markets.businessinsider.comRegeneron (REGN) Receives a Buy from JefferiesDecember 21 at 2:23 AM | markets.businessinsider.comRegeneron to advance two Factor XI antibodies into broad Phase 3 programDecember 20 at 8:06 AM | markets.businessinsider.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Principal Financial Group Inc.Principal Financial Group Inc. lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 173,092 shares of the biopharmaceutical company's stockDecember 20 at 5:17 AM | marketbeat.comRegeneron Pharmaceuticals (NASDAQ:REGN) Coverage Initiated by Analysts at Canaccord Genuity GroupDecember 20 at 3:55 AM | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Rating Lowered to Hold at Canaccord Genuity GroupDecember 20 at 2:59 AM | americanbankingnews.comRegeneron Pharmaceuticals Inc (REGN) Announces Positive Phase 2 Results for Novel ...December 19 at 7:08 AM | gurufocus.comRegeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept ResultsDecember 19 at 7:00 AM | globenewswire.comRegeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 12-Month Low - Here's WhyRegeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 52-Week Low - Time to Sell?December 19 at 6:17 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the twenty-three ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sellDecember 19 at 2:26 AM | marketbeat.comRegeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Lowered by Canaccord Genuity GroupCanaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday.December 18 at 6:28 AM | marketbeat.comLeerink Partners Keeps Their Hold Rating on Regeneron (REGN)December 18 at 4:53 AM | markets.businessinsider.comWhat 25 Analyst Ratings Have To Say About Regeneron PharmaceuticalsDecember 17, 2024 | benzinga.comCanaccord Genuity Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Hold RecommendationDecember 17, 2024 | msn.comRegeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 17, 2024 | globenewswire.comIs Regeneron Pharmaceuticals, Inc. (REGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?December 17, 2024 | insidermonkey.comRegeneron Pharmaceuticals (NASDAQ:REGN) Now Covered by Canaccord Genuity GroupCanaccord Genuity Group began coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday. They issued a "hold" rating and a $165.00 target price on the stock.December 17, 2024 | marketbeat.comRegeneron posts Phase 3 win for Eylea HD in retinal vein occlusionDecember 17, 2024 | seekingalpha.comRegeneron Pharma: Phase 3 Trial With EYLEA HD 8 Mg Meets Primary Endpoint - Quick FactsDecember 17, 2024 | markets.businessinsider.comIs Regeneron Pharmaceuticals, Inc. (REGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?December 17, 2024 | msn.comRegeneron settles patent lawsuit over protein for testing COVID-19 treatmentsDecember 17, 2024 | reuters.comRegeneron Pharmaceuticals Inc (REGN) Achieves High Sustainability RankingsDecember 16, 2024 | gurufocus.comRegeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive YearDecember 16, 2024 | globenewswire.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Lord Abbett & CO. LLCLord Abbett & CO. LLC lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 25.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 64,081 shares of the biopharmDecember 15, 2024 | marketbeat.comRep. Jonathan L. Jackson Unloads Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) SharesRepresentative Jonathan L. Jackson (D-Illinois) recently sold shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). In a filing disclosed on December 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Regeneron Pharmaceuticals stock on November 1st. The trade occDecember 15, 2024 | marketbeat.comRep. Jonathan L. Jackson Sells Off Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Representative Jonathan L. Jackson (D-Illinois) recently sold shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). In a filing disclosed on December 12th, the Representative disclosed that they had sold between $15,001 and $50,000 in Regeneron Pharmaceuticals stock on November 13th. The trade oDecember 15, 2024 | marketbeat.com1,520 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Oddo BHF Asset Management SasOddo BHF Asset Management Sas purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 1,520 shares of the biopharmaceutical company's stock, valued at approximaDecember 14, 2024 | marketbeat.comWilmington Savings Fund Society FSB Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Wilmington Savings Fund Society FSB raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 193.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,810 shares of thDecember 14, 2024 | marketbeat.comRegeneron Pharmaceuticals (NASDAQ:REGN) Hits New 52-Week Low - Time to Sell?Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 12-Month Low - Here's WhyDecember 13, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Franklin Resources Inc.Franklin Resources Inc. lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,896,086 shares of the biopharmaceutical company's stocDecember 13, 2024 | marketbeat.comTeachers Retirement System of The State of Kentucky Decreases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Teachers Retirement System of The State of Kentucky reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 48.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutDecember 13, 2024 | marketbeat.comRegeneron Pharmaceuticals' (REGN) "Underperform" Rating Reaffirmed at Bank of AmericaDecember 13, 2024 | americanbankingnews.comBlankinship & Foster LLC Buys New Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Blankinship & Foster LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,980 shares of the biopharmaceutical cDecember 12, 2024 | marketbeat.comWorld Investment Advisors LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)World Investment Advisors LLC acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 42,066 shares of the biopharmaceuticDecember 12, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Lowered by Sanctuary Advisors LLCSanctuary Advisors LLC decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 20.7% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 35,938 shares of the biopharmaceutical company's stock after selling 9,361 shares during tDecember 12, 2024 | marketbeat.comPine Valley Investments Ltd Liability Co Purchases 848 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Pine Valley Investments Ltd Liability Co increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 19.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,303 sharesDecember 12, 2024 | marketbeat.comVirtu Financial LLC Makes New $6.36 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Virtu Financial LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 6,054 shares of the biopharmaceutical company's stock, valued at approximately $6,36December 12, 2024 | marketbeat.comToronto Dominion Bank Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Toronto Dominion Bank grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 54,719 shares of the biopharmaceutical company's stock after acquiring an additionDecember 12, 2024 | marketbeat.comRegeneron reinstated with an Underperform at BofADecember 10, 2024 | markets.businessinsider.comRegeneron Pharmaceuticals (REGN): Sales Struggles and Future ProspectsDecember 10, 2024 | insidermonkey.comBank of America Reaffirms Underperform Rating for Regeneron Pharmaceuticals (NASDAQ:REGN)Bank of America restated an "underperform" rating and issued a $565.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday.December 10, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Geode Capital Management LLCGeode Capital Management LLC lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,272,261 shares of the biopharmaceutical company'December 10, 2024 | marketbeat.comVestcor Inc Purchases 654 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Vestcor Inc raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,590 shares of the biopharmaceutical company's stock after buying anDecember 10, 2024 | marketbeat.comOdronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of LymphomaDecember 9, 2024 | globenewswire.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Lifted by Groupama Asset ManagmentGroupama Asset Managment grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 7.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 71,277 shares of the biopharmaceDecember 9, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Nomura Asset Management Co. Ltd.Nomura Asset Management Co. Ltd. raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 86,004 shares of the bioDecember 9, 2024 | marketbeat.comY Intercept Hong Kong Ltd Purchases Shares of 9,425 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Y Intercept Hong Kong Ltd purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 9,425 shares of tDecember 9, 2024 | marketbeat.comKovitz Investment Group Partners LLC Has $3.88 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Kovitz Investment Group Partners LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 54.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor ownedDecember 9, 2024 | marketbeat.comNational Bank of Canada FI Has $74.81 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)National Bank of Canada FI boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 66.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 71,159 shares of the biopDecember 8, 2024 | marketbeat.comRegeneron Pharmaceuticals Inc (REGN) Announces Promising Phase 3 Trial Results for Poze-Cemdi ...December 8, 2024 | gurufocus.com Get Regeneron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin REGN Media Mentions By Week REGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. REGN News Sentiment▼0.450.60▲Average Medical News Sentiment REGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. REGN Articles This Week▼2819▲REGN Articles Average Week Get Regeneron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Amgen News Vertex Pharmaceuticals News Gilead Sciences News Alnylam Pharmaceuticals News Biogen News United Therapeutics News Neurocrine Biosciences News Incyte News BioMarin Pharmaceutical News Exact Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:REGN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free REGN Stock Alerts